Raymond James and Cantor both released bullish notes on uniQure (NASDAQ:QURE) Tuesday in the wake of news that the company ...

UniQure (QURE) stock shot up 90% on news the company had reached an agreement with the FDA on an accelerated approval pathway ...

Crucially for the Netherlands-based biopharma company, the FDA has said that the composite Unified Huntington's Disease ...

Qure (NASDAQ:QURE – Get Free Report) was upgraded by research analysts at StockNews.com to a “sell” rating in a research note issued to investors on Wednesday. Other research analysts have also ...

Verition Fund Management LLC lowered its position in uniQure (NASDAQ:QURE – Free Report) by 77.9% during the third quarter, ...

Dutch gene therapy company uniQure saw its shares rocket 86% to $13.57 today, after it reached agreement with the US Food and ...

Walleye Capital LLC purchased a new stake in uniQure (NASDAQ:QURE – Free Report) in the third quarter, according to the ...

Qure stock surges after FDA agrees on an accelerated approval pathway for its Huntington's disease treatment, AMT-130.

The FDA will allow uniQure NV to seek accelerated approval for its Huntington’s disease gene therapy more than doubled the ...

Qure's AMT-130 shows promising results for Huntington’s disease. Learn why QURE stock faces commercialization challenges ...

Shares of uniQure (QURE) have gained 5.2% over the past four weeks to close the last trading session at $6.02, but there could still be a solid upside left in the stock if short-term price targets ...

U.S. Food and Drug Administration (FDA) agrees that data from ongoing Phase I/II studies compared to a natural history external control may serve as the primary basis for a Biologics License ...